IL-RF-IDEAS
14.7.2020 17:02:05 CEST | Business Wire | Press release
rf IDEAS is proud to have received the HP JetAdvantage Partner Award for Customer Focus, presented by HP during its 2020 Partner Conference, held online for participant safety from May 18 to May 22.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005170/en/
rf IDEAS is a leading manufacturer of credential readers for logical access and authentication. The HP JetAdvantage Partner Program offers services and resources to help solution providers accelerate development, simplify deployment and streamline integration with HP imaging and printing devices. Through the program, HP and rf IDEAS have worked together for more than 12 years to bring contactless authentication and identification to HP enterprise applications and to HP JetAdvantage Solutions Partners worldwide.
One quality that sets rf IDEAS apart is the company’s unwavering commitment to customer success. David Cottingham, president of rf IDEAS, said, “We have built a supply chain to support HP in multiple routes to market worldwide, including direct MPS and indirect channel distribution. HP appreciates our unfailing ability to support global customer rollouts and to respond to any issue with creative thinking and flexible execution.”
In announcing the Partner Award for Customer Focus, HP’s vice president for PSS commercial software solutions, Jeff Schaus, described rf IDEAS as, “a partner that goes above and beyond when it comes to ensuring our customers have what they need in a timely manner.” Schaus offered examples including the distribution of an rf IDEAS® reader solution to 12 different countries in just two weeks and the development of a new solution that didn’t exist on the HP corporate price list, satisfying customer requests on an expedited timeframe.
Prior to the 2020 Customer Focus award, rf IDEAS has also been recognized by HP with the Partner in Excellence award in 2014, Partner Collaboration in Excellence award in 2016 and Partner Sales Excellence award in 2017. “All of this shows a dedication to the customer that is essential to our joint business,” Schaus said.
About rf IDEAS
rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, government and enterprise. Backed by the company’s strong partnerships with leading identity access management providers rf IDEAS readers enable innovative solutions for single sign-on, secure printing, attendance tracking and other applications that require authentication. rf IDEAS readers support nearly all credentials worldwide including the growing set of mobile credentials. For more information, visit www.rfIDEAS.com .
rf IDEAS® and WAVE ID® are registered trademarks of rf IDEAS, Inc. Trademarks not belonging to rf IDEAS are property of their respective companies.
©2020 rf IDEAS, Inc. All rights reserved. Products are subject to change without notice.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005170/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom